Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113878 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
A Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Carcinoma, Squamous Cell of Head and Neck, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02113878 is a Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Carcinoma, Squamous Cell of Head and Neck that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 23 participants, below the 90-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02113878, a Phase 1 study of HPV Positive Oropharyngeal Squamous Cell Carcinoma and Carcinoma, Squamous Cell of Head and Neck, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG BKM120
- RADIATION Intensity-modulated radiotherapy (IMRT)
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2022-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02113878
The ClinicalTrials.gov registry entry for NCT02113878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with HPV Positive Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02113878 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02113878 about?
NCT02113878 is a clinical study titled "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck". This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
What is the current status of trial NCT02113878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-09-29. Estimated completion is 2022-01-01.
What conditions does trial NCT02113878 study?
This clinical trial studies the following conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx.
What interventions are being tested in trial NCT02113878?
The interventions under investigation include: Cisplatin (DRUG), BKM120 (DRUG), Intensity-modulated radiotherapy (IMRT) (RADIATION).
Who is sponsoring clinical trial NCT02113878?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02113878 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
RECRUITING · Phase 1
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
HPV Positive Oropharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Carcinoma, Squamous Cell of Head and Neck
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.